Vericel Corporation
VCELVericel Corporation (VCEL) is a biotechnology company specializing in the development and commercialization of autologous cell therapy products for the treatment of sports-related injuries, including cartilage and tendon repair. The company focuses on regenerative medicine technologies aimed at improving patient outcomes in musculoskeletal conditions.
Company News
Vericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI ...
Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation for approximately $31 million in Q3 2025, reducing its stake while the biotech company reported strong quarterly revenue growth of 17%.
MediWound reported a 43% quarterly revenue increase to $5.7 million, improved gross margins, and advanced its Phase III EscharEx trial while establishing strategic partnerships with wound care leaders.
Vericel reported Q2 2025 revenue growth of 20% to $63.2 million, driven by strong MACI cartilage repair franchise performance. The company expanded gross margins to 74% and narrowed net loss per share, while preparing for potential market expansion into ankle cartilage repair.
Vericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.
